O	0	14	Cardiovascular
O	15	22	effects
O	23	25	of
B-intervention	26	35	tamoxifen
O	36	38	in
O	39	44	women
O	45	49	with
O	50	53	and
O	54	61	without
O	62	67	heart
O	68	75	disease
O	75	76	:
O	77	83	breast
O	84	90	cancer
O	91	101	prevention
O	102	107	trial
O	107	108	.

O	109	117	National
O	118	126	Surgical
O	127	135	Adjuvant
O	136	142	Breast
O	143	146	and
O	147	152	Bowel
O	153	160	Project
O	161	167	Breast
O	168	174	Cancer
O	175	185	Prevention
O	186	191	Trial
O	192	205	Investigators
O	205	206	.

O	207	210	The
O	211	218	overall
O	219	225	effect
O	226	228	of
O	229	241	prophylactic
O	242	251	tamoxifen
O	252	254	in
O	255	260	women
O	261	268	depends
O	269	271	on
O	272	275	the
O	276	283	balance
O	284	291	between
O	292	295	the
O	296	303	effects
O	304	306	of
O	307	310	the
O	311	315	drug
O	315	316	,
O	317	322	which
O	323	330	include
O	331	341	preventing
O	342	348	breast
O	349	355	cancer
O	356	359	and
O	360	368	altering
O	369	383	cardiovascular
O	384	388	risk
O	388	389	.

O	390	392	In
O	393	394	a
O	395	401	recent
O	402	410	clinical
O	411	416	trial
O	416	417	,
O	418	432	postmenopausal
O	433	441	estrogen
O	441	442	-
O	442	451	progestin
O	452	459	therapy
O	460	463	was
O	464	469	shown
O	470	472	to
O	473	481	increase
O	482	485	the
O	486	490	risk
O	491	493	of
O	494	499	early
O	500	514	cardiovascular
O	515	521	events
O	522	527	among
O	528	533	women
O	534	538	with
O	539	540	a
O	541	548	history
O	549	551	of
B-condition	552	560	coronary
I-condition	561	566	heart
I-condition	567	574	disease
I-condition	575	576	(
I-condition	576	579	CHD
I-condition	579	580	)
O	580	581	.

O	582	585	The
O	586	600	cardiovascular
O	601	608	effects
O	609	611	of
O	612	621	tamoxifen
O	622	624	in
O	625	630	women
O	631	635	with
O	636	639	and
O	640	647	without
O	648	651	CHD
O	652	655	are
O	656	659	not
O	660	665	known
O	665	666	.

O	667	670	The
O	671	679	National
O	680	688	Surgical
O	689	697	Adjuvant
O	698	704	Breast
O	705	708	and
O	709	714	Bowel
O	715	722	Project
O	723	729	Breast
O	730	736	Cancer
O	737	747	Prevention
O	748	753	Trial
O	754	755	(
O	755	759	BCPT
O	759	760	)
O	761	763	is
O	764	767	the
O	768	772	only
O	773	781	clinical
O	782	787	trial
O	788	792	that
O	793	801	provides
O	802	806	data
O	807	809	to
O	810	816	assess
O	817	820	the
O	821	835	cardiovascular
O	836	843	effects
O	844	846	of
O	847	856	tamoxifen
O	857	859	in
O	860	865	women
O	866	870	with
O	871	874	and
O	875	882	without
O	883	886	CHD
O	886	887	.

O	888	889	A
O	890	895	total
O	896	898	of
B-total-participants	899	901	13
I-total-participants	902	905	388
B-eligibility	906	911	women
I-eligibility	912	914	at
I-eligibility	915	924	increased
I-eligibility	925	929	risk
I-eligibility	930	933	for
I-eligibility	934	940	breast
I-eligibility	941	947	cancer
O	948	952	were
O	953	961	randomly
O	962	970	assigned
O	971	973	in
O	974	977	the
O	978	982	BCPT
O	983	985	to
O	986	993	receive
O	994	1000	either
O	1001	1010	tamoxifen
O	1011	1012	(
O	1012	1014	20
O	1015	1017	mg
O	1017	1018	/
O	1018	1021	day
O	1021	1022	)
O	1023	1025	or
B-control	1026	1033	placebo
O	1033	1034	.

O	1035	1049	Cardiovascular
O	1050	1056	follow
O	1056	1057	-
O	1057	1059	up
O	1060	1063	was
O	1064	1073	available
O	1074	1077	for
B-total-participants	1078	1080	13
I-total-participants	1081	1084	194
O	1085	1090	women
O	1090	1091	,
O	1092	1096	1048
O	1097	1099	of
O	1100	1104	whom
O	1105	1108	had
O	1109	1114	prior
O	1115	1123	clinical
O	1124	1127	CHD
O	1127	1128	.

O	1129	1134	Fatal
O	1135	1138	and
O	1139	1147	nonfatal
O	1148	1158	myocardial
O	1159	1169	infarction
O	1169	1170	,
O	1171	1179	unstable
O	1180	1186	angina
O	1186	1187	,
O	1188	1191	and
O	1192	1198	severe
O	1199	1205	angina
O	1206	1210	were
O	1211	1220	tabulated
O	1221	1222	(
O	1222	1226	mean
O	1227	1233	follow
O	1233	1234	-
O	1234	1236	up
O	1236	1237	:
O	1238	1240	49
O	1241	1247	months
O	1247	1248	)
O	1248	1249	.

O	1250	1253	All
O	1254	1265	statistical
O	1266	1271	tests
O	1272	1276	were
O	1277	1280	two
O	1280	1281	-
O	1281	1286	sided
O	1286	1287	.

B-outcome	1288	1302	Cardiovascular
I-outcome	1303	1308	event
I-outcome	1309	1314	rates
O	1315	1319	were
O	1320	1323	not
O	1324	1337	statistically
O	1338	1351	significantly
O	1352	1361	different
O	1362	1369	between
O	1370	1375	women
O	1376	1384	assigned
O	1385	1387	to
O	1388	1395	receive
O	1396	1405	tamoxifen
O	1406	1409	and
O	1410	1415	those
O	1416	1424	assigned
O	1425	1427	to
O	1428	1435	receive
O	1436	1443	placebo
O	1443	1444	,
O	1445	1456	independent
O	1457	1459	of
O	1460	1463	pre
O	1463	1464	-
O	1464	1472	existing
O	1473	1476	CHD
O	1476	1477	.

O	1478	1483	Among
O	1484	1489	women
O	1490	1497	without
O	1498	1501	CHD
O	1502	1503	(
B-intervention-participants	1503	1507	6074
O	1508	1510	on
O	1511	1520	tamoxifen
O	1521	1527	versus
B-control-participants	1528	1532	6072
O	1533	1535	on
O	1536	1543	placebo
O	1543	1544	)
O	1544	1545	,
O	1546	1550	risk
O	1551	1557	ratios
O	1558	1559	(
O	1559	1561	95
O	1561	1562	%
O	1563	1573	confidence
O	1574	1583	intervals
O	1584	1585	[
O	1585	1588	CIs
O	1588	1589	]
O	1589	1590	)
O	1591	1594	for
O	1595	1604	tamoxifen
O	1605	1610	users
O	1611	1615	were
O	1616	1617	1
O	1617	1618	.
O	1618	1620	75
O	1621	1622	(
O	1622	1623	0
O	1623	1624	.
O	1624	1626	44
O	1627	1629	to
O	1630	1631	8
O	1631	1632	.
O	1632	1634	13
O	1634	1635	)
O	1636	1639	for
B-outcome	1640	1645	fatal
I-outcome	1646	1656	myocardial
I-outcome	1657	1667	infarction
I-outcome	1667	1668	,
O	1669	1670	1
O	1670	1671	.
O	1671	1673	11
O	1674	1675	(
O	1675	1676	0
O	1676	1677	.
O	1677	1679	55
O	1680	1682	to
O	1683	1684	2
O	1684	1685	.
O	1685	1687	28
O	1687	1688	)
O	1689	1692	for
B-outcome	1693	1701	nonfatal
I-outcome	1702	1712	myocardial
I-outcome	1713	1723	infarction
O	1723	1724	,
O	1725	1726	0
O	1726	1727	.
O	1727	1729	69
O	1730	1731	(
O	1731	1732	0
O	1732	1733	.
O	1733	1735	29
O	1736	1738	to
O	1739	1740	1
O	1740	1741	.
O	1741	1743	57
O	1743	1744	)
O	1745	1748	for
B-outcome	1749	1757	unstable
I-outcome	1758	1764	angina
O	1764	1765	,
O	1766	1769	and
O	1770	1771	0
O	1771	1772	.
O	1772	1774	83
O	1775	1776	(
O	1776	1777	0
O	1777	1778	.
O	1778	1780	32
O	1781	1783	to
O	1784	1785	2
O	1785	1786	.
O	1786	1788	10
O	1788	1789	)
O	1790	1793	for
B-outcome	1794	1800	severe
I-outcome	1801	1807	angina
O	1807	1808	.

O	1809	1811	In
O	1812	1817	women
O	1818	1822	with
O	1823	1826	CHD
O	1827	1828	(
B-intervention-participants	1828	1831	516
O	1832	1834	on
O	1835	1844	tamoxifen
O	1845	1851	versus
B-control-participants	1852	1855	532
O	1856	1858	on
O	1859	1866	placebo
O	1866	1867	)
O	1867	1868	,
O	1869	1873	risk
O	1874	1880	ratios
O	1881	1882	(
O	1882	1884	95
O	1884	1885	%
O	1886	1889	CIs
O	1889	1890	)
O	1891	1894	for
O	1895	1904	tamoxifen
O	1905	1910	users
O	1911	1915	were
O	1916	1917	0
O	1917	1918	.
O	1918	1920	00
O	1921	1922	(
O	1922	1923	0
O	1924	1926	to
O	1927	1928	1
O	1928	1929	.
O	1929	1931	58
O	1931	1932	)
O	1933	1936	for
B-outcome	1937	1942	fatal
I-outcome	1943	1953	myocardial
I-outcome	1954	1964	infarction
O	1964	1965	,
O	1966	1967	1
O	1967	1968	.
O	1968	1970	25
O	1971	1972	(
O	1972	1973	0
O	1973	1974	.
O	1974	1976	32
O	1977	1979	to
O	1980	1981	5
O	1981	1982	.
O	1982	1984	18
O	1984	1985	)
O	1986	1989	for
B-outcome	1990	1998	nonfatal
I-outcome	1999	2009	myocardial
I-outcome	2010	2020	infarction
O	2020	2021	,
O	2022	2023	2
O	2023	2024	.
O	2024	2026	26
O	2027	2028	(
O	2028	2029	0
O	2029	2030	.
O	2030	2032	87
O	2033	2035	to
O	2036	2037	6
O	2037	2038	.
O	2038	2040	55
O	2040	2041	)
O	2042	2045	for
B-outcome	2046	2054	unstable
I-outcome	2055	2061	angina
O	2061	2062	,
O	2063	2066	and
O	2067	2068	1
O	2068	2069	.
O	2069	2071	39
O	2072	2073	(
O	2073	2074	0
O	2074	2075	.
O	2075	2077	23
O	2078	2080	to
O	2081	2082	9
O	2082	2083	.
O	2083	2085	47
O	2085	2086	)
O	2087	2090	for
B-outcome	2091	2097	severe
I-outcome	2098	2104	angina
O	2104	2105	.

O	2106	2111	There
O	2112	2115	was
O	2116	2118	no
O	2119	2127	evidence
O	2128	2132	that
O	2133	2136	the
O	2137	2141	lack
O	2142	2144	of
O	2145	2156	association
O	2157	2164	between
O	2165	2174	tamoxifen
O	2175	2178	and
O	2179	2193	cardiovascular
O	2194	2200	events
O	2201	2204	was
O	2205	2212	related
O	2213	2215	to
O	2216	2218	an
O	2219	2224	early
O	2225	2233	increase
O	2234	2236	in
O	2237	2241	risk
O	2242	2246	that
O	2247	2250	may
O	2251	2255	have
O	2256	2260	been
O	2261	2267	offset
O	2268	2270	by
O	2271	2272	a
O	2273	2277	late
O	2278	2286	decrease
O	2287	2289	in
O	2290	2294	risk
O	2294	2295	.

O	2296	2300	When
O	2301	2305	used
O	2306	2309	for
O	2310	2316	breast
O	2317	2323	cancer
O	2324	2334	prevention
O	2335	2337	in
O	2338	2343	women
O	2344	2348	with
O	2349	2351	or
O	2352	2359	without
O	2360	2365	heart
O	2366	2373	disease
O	2373	2374	,
O	2375	2384	tamoxifen
O	2385	2387	is
O	2388	2391	not
O	2392	2402	associated
O	2403	2407	with
O	2408	2418	beneficial
O	2419	2421	or
O	2422	2429	adverse
O	2430	2444	cardiovascular
O	2445	2452	effects
O	2452	2453	.
